CSBio CSBio

X
[{"orgOrder":0,"company":"Elixiron Immunotherapeutics","sponsor":"Alzheimer's Association","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"Elixiron Immunotherapeutics Awarded Alzheimer's Association Grant to Target Microglia in Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"TAIWAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Elixiron Immunotherapeutics"},{"orgOrder":0,"company":"Elixiron Immunotherapeutics","sponsor":"Pangu Capital","pharmaFlowCategory":"D","amount":"$27.0 million","upfrontCash":"Undisclosed","newsHeadline":"Elixiron Immunotherapeutics Announces Closing of $27 Million Series A-1 Financing Round to Progress Alzheimer's Disease and Vitiligo","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"TAIWAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Elixiron Immunotherapeutics"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Proceeds will be used to advance phase 1 trials of two pipeline candidates, EI-1071 and EI-001 and take three immuno-oncology assets towards IND applications .

            Lead Product(s): EI-1071

            Therapeutic Area: Neurology Product Name: EI-1071

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Pangu Capital

            Deal Size: $27.0 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing August 23, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Grant Program will support a U.S. FDA-approved first-in-human phase 1 clinical trial of its lead drug candidate, EI1071, an orally available, highly potent Colony-Stimulating Factor 1 Receptor (CSF1R) inhibitor.

            Lead Product(s): EI1071

            Therapeutic Area: Neurology Product Name: EI1071

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Alzheimer's Association

            Deal Size: $1.0 million Upfront Cash: Undisclosed

            Deal Type: Funding August 26, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY